15 November 2011
New healthcare research may give hope to women with the most severe cases of breast cancer, according to new reports.
Scientists at the George Mason University have found that women with the deadliest types of advanced cancer such as inflammatory breast cancer can now benefit from a new type of treatment pinpointed in studies.
The researchers discovered a drug that targets the protein of the cancer rather than the genes. It was originally developed for non-small cell lung cancer.
Emanuel 'Chip' Petricoin, co-director of Mason's Center for Applied Proteomics and Molecular Medicine, said: "While many think of cancer as a genomic disease, it's actually a proteomic disease. What is actually deranged in the cancer cells are protein pathways."
He added it has now become clear that the one-size-fits-all approach is not successful as not every patient has the same network of activated proteins.
Inflammatory breast cancer kills about half the women who have it within five years.
According to data from Cancer Research UK, breast cancer accounts for 31 per cent of all cancer cases in women.
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.